4SC's vidofludimus fails to meet primary endpoint in rheumatoid arthritis
This article was originally published in Scrip
Executive Summary
German biotechnology firm 4SC's lead drug candidate vidofludimus has failed to meet the primary efficacy endpoint in a Phase IIb trial in rheumatoid arthritis, its lead indication. The news has wiped more than a third off the company's share price.
You may also be interested in...
UK Reimbursement Decisions Focus Mostly On Cancer
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
Deal Watch: Valeant Sells Off iNova To Finance Debt-Reduction Efforts
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Pfizer/Astellas Amend Trial To Position Xtandi In Early Prostate Cancer
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.